39例血管免疫母细胞性T细胞淋巴瘤的临床特点和预后分析

发布时间：2018-03-07 18:13

  本文选题：血管免疫母细胞性T细胞淋巴瘤　切入点：临床特征　出处：《临床肿瘤学杂志》2017年03期 　论文类型：期刊论文

【摘要】：目的探讨血管免疫母细胞性T细胞淋巴瘤(AITL)的临床特征和预后因素。方法回顾性分析安徽医科大学第一附属医院2009年2月至2016年6月收治的39例AITL患者的临床资料。39例AITL患者治疗均采用全身化疗,其中29例行标准CHOP方案,化疗2个周期后评价客观疗效。采用Kaplan-Meier方法进行生存分析,各亚组间的比较采用Logrank检验。结果 39例患者中位发病年龄为62岁,男女比例为2.5∶1,Ann Arbor分期Ⅲ~Ⅳ期者30例,ECOG评分1者13例,乳酸脱氢酶(LDH)升高者29例,β2微球蛋白(β2-MG)升高者20例,低白蛋白水平者19例,淋巴细胞数增多者19例,结外侵犯数目1者12例,有浆膜腔积液者16例,Ki-67≥50%者11例,IPI评分2~5者33例。全组患者获完全缓解(CR)9例,部分缓解(PR)14例,有效率(RR)为58.9%。全组患者预期1、2、3年生存率分别为81%、59%、40%,中位OS为27个月(95%CI:15.139~38.861个月),中位PFS为9个月(95%CI:1.317~16.683个月)。单因素分析显示,ECOG评分1、结外侵犯数目1、有浆膜腔积液、Ki-67≥50%与AITL患者的不良预后相关。结论 AITL是一种侵袭性强、预后不良的疾病。患者治疗前ECOG评分、结外侵犯数目、是否存在浆膜腔积液和Ki-67水平可作为其预后的参考因素。
[Abstract]:Objective to investigate the clinical features and prognostic factors of vascular immunoblastic T-cell lymphoma (AITL). Methods the clinical data of 39 patients with AITL admitted from February 2009 to June 2016 in the first affiliated Hospital of Anhui Medical University were retrospectively analyzed. Materials. 39 patients with AITL were treated with systemic chemotherapy. 29 cases were treated with standard CHOP regimen, objective curative effect was evaluated after 2 cycles of chemotherapy, survival analysis was performed by Kaplan-Meier method and Logrank test was used to compare the subgroups. Results the median onset age of 39 patients was 62 years old. The ratio of male to female was 2.5: 1 Ann Arbor stage 鈪，

本文编号：1580393